The majority of patients with pulmonary arterial hypertension, except for a few special circumstances, will begin treatment on combination therapy, instead of monotherapy, because combination therapy has been shown in trials to ahve better outcomes, explained Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
The majority of patients with pulmonary arterial hypertension, except for a few special circumstances, will begin treatment on combination therapy, instead of monotherapy, because combination therapy has been shown in trials to ahve better outcomes, explained Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Transcript
How do you weigh the benefits of monotherapy versus combination therapy in patients with pulmonary hypertension?
I think nowadays, I wouldn't normally, I would no longer start monotherapy. I would start with combination therapy in pulmonary arterial hypertension, except in very special circumstances, such as you have a responder to nitric oxide—a vasoreactivity test, in other words—and they would go onto long-term treatment with calcium channel blockers. And there are a few other circumstances. Perhaps patients with portal hypertension or pulmonary veno-occlusive disease, one would use monotherapy.
But in the vast majority of patients with pulmonary arterial hypertension, I would use initial combination therapy, because it has been shown in clinical trials of initial combination that the outcomes are better and in sequential combination that the outcomes are better too. There are a small group of patients who've been on monotherapy for 5 or 10 years, and they're completely stable. And I wouldn't go around changing them at all. But the majority of patients now are going to be on combination therapy, if not initially, very quickly.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More